This study will follow participants who completed the TED-C14-006 study. The purpose of this study is to evaluate the long-term safety and efficacy of teduglutide in pediatric participants with Short Bowel Syndrome (SBS). This study will also offer teduglutide treatment to eligible participants, regardless of treatment received in TED-C14-006 or SHP633-301.
COMPLETED
Inclusion Criteria:
1. Participant provides written informed consent (participant, parent or legal guardian and, as appropriate, informed assent) to participate in the study before completing any study-related procedures.
2. Participant completed the TED-C14-006 or SHP633-301 studies (including participants in the standard of care treatment arms). Participants are considered to have completed SHP633-301 if they completed study assessments through week 24.
3. Participant understands and is willing and able to fully adhere to study requirements as defined in this protocol.
Exclusion Criteria:
1\. There are no exclusion criteria for this study.
PHASE3
ALL
N/A
N/A
2025-03-28
N/A
DRUG
OTHER
DEVICE
DEVICE
TED
SOC
Syringe
Needle
For more information and to contact the study team: